On Wednesday, Stifel, a financial services firm, increased the price target for Boston Scientific Corporation (NYSE:BSX) shares to $83 from $70, while reiterating a Buy rating on the stock. The adjustment reflects the analyst's confidence in the company's growth potential, driven by key innovations in cardiology.
The analyst highlighted three critical factors that could contribute to Boston Scientific's continued outperformance. First, the success of Farapulse in maintaining its early lead in the market is crucial. Boston Scientific is expected to evolve the technology and use it to boost sales of other electrophysiology (EP) division products, such as mapping and diagnostic catheters.
Secondly, the growth trajectory of the Watchman device could be significantly impacted by the outcomes of the CHAMPION-AF and OPTION clinical trials, which are anticipated in 2026 and 2025, respectively. Positive results could potentially triple the total addressable market (TAM) for the Watchman in the United States.
Lastly, the analyst pointed to the forthcoming one-year data from the ACURATE NEO2/ACURATE Prime TAVR trials, expected by the end of 2024. A successful outcome, followed by FDA approval in 2025, could provide an additional growth opportunity for Boston Scientific in the U.S. market, though this potential has not been factored into the current model.
The firm's updated projections and long-range planning (LRP) suggest that Boston Scientific is well-positioned for robust growth and market outperformance in the coming years. The raised price target to $83 reflects the firm's optimism about the company's innovation pipeline and its ability to capitalize on these advancements.
InvestingPro Insights
As Boston Scientific Corporation (NYSE:BSX) continues to make waves in the healthcare sector with its innovative cardiology products, real-time data and insights from InvestingPro provide a deeper look into the company's financial health and market performance. With a robust market capitalization of $107.95 billion, Boston Scientific is showcasing a solid presence in the industry. The company's revenue growth is impressive, with a 12.29% increase over the last twelve months as of Q1 2023 and an even more remarkable quarterly growth of 14.9% in Q1 2023.
InvestingPro Tips highlight that Boston Scientific is expected to see net income growth this year, which aligns with the analyst's positive outlook. Moreover, the company is trading at a low P/E ratio relative to near-term earnings growth, suggesting that the stock could be undervalued considering its growth prospects. These financial metrics, coupled with the company's low price volatility and position as a prominent player in the Healthcare Equipment & Supplies industry, underscore the reasons behind Stifel's increased price target and Buy rating.
For those looking to delve deeper into Boston Scientific's performance and potential, InvestingPro offers additional insights and tips. With a total of 17 InvestingPro Tips available, investors can gain a comprehensive understanding of the company's financial nuances and market position. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription and unlock the full spectrum of analytical tools and expert insights that InvestingPro has to offer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.